StreetAlpha.app
Home › Stocks › RZLT

Rezolute, Inc. (RZLT)

Healthcare
$3.92
▼ −6.67%
LAST CLOSE · NOV 20

Rezolute is a Redwood City pharmaceutical company developing ersodetug to treat low blood sugar caused by hyperinsulinism. It last closed at $3.92 on Nov 20, down 6.67% on the day. The next earnings report for RZLT is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, RZLT reported EPS of -$0.18. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months RZLT insiders bought $236K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is RZLT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RZLT.

Key Stats

Last 12 months
Results
Net income
−$77.9M
EPS (diluted)
−$0.75
Valuation
Market cap
$379.2M
96.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$8.2M
At Sep 30
Shareholder equity
$85.9M
Shares outstanding
96.7M
At Nov 2
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: −$41.1M−$41.1MFY2022FY2023: −$51.8M−$51.8MFY2023FY2024: −$68.5M−$68.5MFY2024FY2025: −$74.4M−$74.4MFY2025FY2026: −$77.6M−$77.6MFY2026

From RZLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 11
Estimated date · After the close
Reported EPS
-$0.18
Quarter ended Sep 2026
Year ago EPS
-$0.18
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.22Dec '24Mar 2025: -$0.27Mar '25Jun 2025: -$0.26Jun '25Sep 2025: -$0.18Sep '25Dec 2025: -$0.22Dec '25Mar 2026: -$0.16Mar '26Jun 2026: -$0.20Jun '26Sep 2026: -$0.18Sep '26Latest -$0.18
Revenue by quarter
Not enough quarters on file yet.
How RZLT moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 5, 2026After the close+6.6%
Sep 24, 2026After the close−1.0%
May 12, 2026After the close+0.9%
Feb 12, 2026After the close+5.8%
Nov 6, 2025After the close+12.1%
Sep 17, 2025After the close+6.4%
May 13, 2025After the close−4.9%
Feb 12, 2025After the close−1.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RZLTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RZLT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RZLT

Technical Analysis

RZLT · as of the Nov 20 close · updated each morning
Moving sideways

The stock is 1% below its 20 day and 3% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 48). The nearest support is the swing low (Oct 5) at $3.82, and the nearest resistance the 200 day average at $3.95.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 9.5%/day
Key levels
$11.1652 week high+184.7%
$4.39100 day average+12.0%
$4.33Swing high (Oct 29)+10.5%
$4.15Pivot R1+5.9%
$4.0450 day average+3.1%
$4.00Pivot+2.0%
$3.9520 day average+0.8%
$3.95200 day average+0.8%
$3.92Last close
$3.82Swing low (Oct 5)−2.6%
$3.78Pivot S1−3.6%
$1.0752 week low−72.7%
Indicators
RSI (14)48.37Middle of its rangeNeutral
MACD-0.02Above its signal lineBullish
Stochastic60.9Middle of its rangeNeutral
ADX (14)15.8No clear trend
Williams %R-55.4Oversold below −80, overbought above −20Neutral
CCI (20)19.1Oversold below −100, overbought above 100Neutral
Rate of change+1.0%Change over 10 sessionsBullish
ATR (14)$0.37Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RZLT

What happened before

See how RZLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RZLT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RZLT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RZLTHow many large options trades hit RZLT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RZLT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼60 buying vs 76 selling
  • ▼Held by funds -1.9 pts
  • ▼Funds holding -8
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding138146−5.5%
In funds' top 1002−100.0%
Held by funds87.8%89.6%−1.9 pts
New / increased18 / 4239 / 60−39.4%
Reduced / sold out49 / 2730 / 19+55.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RZLT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RZLT Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$236K6 buys · 5 insiders
Sold$00 sales · 0 insiders
Cluster buy: 5 insiders bought $207K between Dec 15 and Dec 16.
2025-12 bought $207K2026-03 bought $29KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 30Daron EvansCFOBuy10,000$2.85$29K
Dec 16, 2025Brian Kenneth RobertsChief Medical OfficerBuy28,000$1.70$48K
Dec 16, 2025Wladimir HogenhuisDirectorBuy5,650$1.69$10K
Dec 15, 2025Sunil Ratilal KarnawatChief Commercial OfficerBuy12,100$1.62$20K
Dec 15, 2025Nevan C ElamCEOBuy32,000$1.59$51K
Dec 15, 2025Daron EvansCFOBuy45,000$1.77$80K
Every insider buy and sale for RZLT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RZLT insider trades →

From SEC Form 4 filings by RZLT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RZLT is in one of them and how their past RZLT trades turned out.

RZLT in the AI portfolios
Loading…

RZLT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RZLT in an article yet. Here's the latest on the wider market.

RZLT in the news

About Rezolute

Rezolute is a pharmaceutical company based in Redwood City, California, that is developing treatments for hypoglycemia, or dangerously low blood sugar, caused by hyperinsulinism. Its main candidate, ersodetug, is an intravenously given antibody that acts on the insulin receptor to help bring blood glucose back into a more normal range. The company is studying the drug in children with congenital hyperinsulinism and in patients with tumor-related hyperinsulinism. Its work is aimed at patients and families affected by these rare conditions, for whom current treatment options are limited.

Headquarters
Redwood City, CA